MASLD co-aggregates with HCC in families-names change, fa(c)ts remain

Abstract

My invited commentary discusses a recent paper published by Ebrahimi et al.^[28]. To this end, the definitions of nonalcoholic fatty liver disease (NAFLD), metabolic dysfunction-associated fatty liver disease (MAFLD), and the most recently proposed metabolic dysfunction-associated steatotic liver disease (MASLD) are reviewed. For brevity, the overarching definition of metabolic fatty liver syndromes (MFLS) is utilized to allude to NAFLD/MAFLD/MASLD collectively, although each nomenclature identifies different diagnostic criteria and distinct patient populations. Ebrahimi and colleagues conducted an analysis using data from the National Swedish Multigeneration archive, involving 38,018 MASLD first-degree relatives (FDRs) and 9,381 MASLD spouses, alongside 197,303 comparator FDRs and 47,572 comparator spouses. These authors followed these groups for a median of 17.6 years and reported a definite familial aggregation of adverse liver-related events among families of MASLD individuals. These events comprise increased relative risks of hepatocellular carcinoma (HCC), major chronic liver disease, and mortality owing to hepatic causes. I comment on this study with reference to the ongoing changes in terminology describing MFLS and to sexual dimorphism exhibited by MFLS. It is concluded that the study by Ebrahimi adds another piece to the puzzle of knowledge requested to implement those precision medicine approaches that are eagerly awaited in the field of MFLS.

Keywords

HCC / MAFLD / MASLD / MFLS / NAFLD / NASH / precision medicine

References

[1] Furman D,Verdin E.Chronic inflammation in the etiology of disease across the life span.Nat Med2019;25:1822-32 PMCID:PMC7147972

[2] Lonardo A.Extra-hepatic cancers in metabolic fatty liver syndromes.Explor Dig DisExplor Dig Dis2023;2:11-7

[3] Cechinel LR,Freishtat RJ.Parental obesity-induced changes in developmental programming.Front Cell Dev Biol2022;10:918080 PMCID:PMC9585252

[4] Ludwig J,McGill DB.Nonalcoholic steatohepatitis: mayo clinic experiences with a hitherto unnamed disease.Mayo Clin Proc1980;55:434-8.

[5] Schaffner F.Nonalcoholic fatty liver disease.Prog Liver Dis1986;8:283-98.

[6] Caldwell SH,Iezzoni JC,Battle EH.Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease.Hepatology1999;29:664-9

[7] Marrero JA,Su GL,Emick DM.NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States.Hepatology2002;36:1349-54

[8] Diehl AM,Ishak KG.Alcohollike liver disease in nonalcoholics. A clinical and histologic comparison with alcohol-induced liver injury.Gastroenterology1988;95:1056-62

[9] Zarghamravanbakhsh P,Poretsky L.Metabolic causes and consequences of nonalcoholic fatty liver disease (NAFLD).Metabol Open2021;12:100149. PMCID:PMC8626571

[10] Ballestri S,Targher G.Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis.J Gastroenterol Hepatol2016;31:936-44

[11] Lonardo A.Perspectives of nonalcoholic fatty liver disease research: a personal point of view.Explor Med2020;1:85-107.

[12] Lugari S,Lonardo A.Metabolic primary liver cancer in adults: risk factors and pathogenic mechanisms.Metab Target Organ Damage2023;3:5.

[13] Singal AG.Rational HCC screening approaches for patients with NAFLD.J Hepatol2022;76:195-201 PMCID:PMC8688224

[14] Eslam M,George J.International Consensus PanelMAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease.Gastroenterology2020;158:1999-2014.e1

[15] Eslam M,Sarin SK.A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement.J Hepatol2020;73:202-9

[16] Chen YG,Chung CH,Chen WL.The association between metabolic risk factors, nonalcoholic fatty liver disease, and the incidence of liver cancer: a nationwide population-based cohort study.Hepatol Int2022;16:807-16.

[17] INOVA. Stigma in NAFLD and NASH: a global survey of patients and providers. Available from: https://www.postersessiononline.eu/173580348_eu/congresos/ILC2023/aula/-THU_453_ILC2023.pdf [Last accessed on 29 Dec 2023]

[18] Rinella ME,Ratziu V.NAFLD Nomenclature consensus groupA multisociety Delphi consensus statement on new fatty liver disease nomenclature.J Hepatol2023;79:1542-56

[19] Churchill’s illustrated medical dictionary. New York: Churchill Livingstone Inc; 1989. Available from: https://www.amazon.com/Churchills-Illustrated-Medical-Dictionary-Koenisberger/dp/0443086915 [Last accessed on 29 Dec 2023]

[20] Medical Dictionary: A-Z. Available from: https://www.merriam-webster.com/medical [Last accessed on 29 Dec 2023]

[21] Medical Dictionary. Available from: https://medical-dictionary.thefreedictionary.com/ [Last accessed on 29 Dec 2023]

[22] Medical dictionary of health terms: Q-Z. Available from: https://www.health.harvard.edu/q-through-z#S-terms [Last accessed on 29 Dec 2023]

[23] Saunders WB. Dorland’s illustrated medical dictionary 26th Edition. Philadelhia; 1985. Available from: https://www.ebay.com/itm/314745545108 [Last accessed on 2 Jan 2024]

[24] Younossi ZM,Alswat K.Global NASH CouncilGlobal survey of stigma among physicians and patients with nonalcoholic fatty liver disease.J Hepatol2023;Online ahead of print

[25] Suzuki A.Nonalcoholic steatohepatitis.Annu Rev Med2017;68:85-98.

[26] Arrese M,Barrera F,Valenti L.Insights into nonalcoholic fatty-liver disease heterogeneity.Semin Liver Dis2021;41:421-34. PMCID:PMC8492194

[27] Lonardo A,Osna N.Effect of cofactors on NAFLD/NASH and MAFLD. A paradigm illustrating the pathomechanics of organ dysfunction.Metab Target Organ Damage2022;2:12 PMCID:PMC9453927

[28] Ebrahimi F,Sun J.Familial coaggregation of MASLD with hepatocellular carcinoma and adverse liver outcomes: nationwide multigenerational cohort study.J Hepatol2023;79:1374-84

[29] Thomas CE,Kuipers AL.NAFLD polygenic risk score and risk of hepatocellular carcinoma in an East Asian population.Hepatol Commun2022;6:2310-21 PMCID:PMC9426386

[30] Abdelmalek MF,Shuster J,Asal NR.Familial aggregation of insulin resistance in first-degree relatives of patients with nonalcoholic fatty liver disease.Clin Gastroenterol Hepatol2006;4:1162-9

[31] Hassan MM,Thomas MB.The association of family history of liver cancer with hepatocellular carcinoma: a case-control study in the United States.J Hepatol2009;50:334-41 PMCID:PMC2658718

[32] Caussy C,Cui J.Familial NAFLD Cirrhosis Research ConsortiumNonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis.J Clin Invest2017;127:2697-704 PMCID:PMC5490764

[33] Tamaki N,Luukkonen PK.Risk of advanced fibrosis in first-degree relatives of patients with nonalcoholic fatty liver disease.J Clin Invest2022;132:e162513. PMCID:PMC9621132

[34] Anand A,Elhence A.Prevalence and predictors of nonalcoholic fatty liver disease in family members of patients with nonalcoholic fatty liver disease.J Clin Exp Hepatol2022;12:362-71 PMCID:PMC9077183

[35] Simon TG,Khalili H,Ludvigsson JF.Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort.Gut2021;70:1375-82 PMCID:PMC8185553

[36] Hagström H,Ekstedt M.99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical.J Hepatol2023;Online ahead of print

[37] Mauvais-Jarvis F,Barnes PJ.Sex and gender: modifiers of health, disease, and medicine.Lancet2020;396:565-82 PMCID:PMC7440877

[38] Ballestri S,Baldelli E,Romagnoli D.NAFLD as a sexual dimorphic disease: role of gender and reproductive status in the development and progression of nonalcoholic fatty liver disease and inherent cardiovascular risk.Adv Ther2017;34:1291-326 PMCID:PMC5487879

[39] Lonardo A.Sexual dimorphism of NAFLD in adults. focus on clinical aspects and implications for practice and translational research.J Clin Med2020;9:1278. PMCID:PMC7288212

[40] Balakrishnan M,Dunn-Valadez S.Women have a lower risk of nonalcoholic fatty liver disease but a higher risk of progression vs men: a systematic review and meta-analysis.Clin Gastroenterol Hepatol2021;19:61-71.e15. PMCID:PMC8796200

[41] Goossens GH,Blaak EE.Sexual dimorphism in cardiometabolic health: the role of adipose tissue, muscle and liver.Nat Rev Endocrinol2021;17:47-66.

[42] Wu EM,Hernandez BY.Gender differences in hepatocellular cancer: disparities in nonalcoholic fatty liver disease/steatohepatitis and liver transplantation.Hepatoma Res2018;4:66 PMCID:PMC6347119

[43] Lonardo A,Chow PKH.Sex disparity in hepatocellular carcinoma owing to NAFLD and non-NAFLD etiology: epidemiological findings and pathobiological mechanisms.Hepatoma Res2020;6:83

[44] Lonardo A,Ballestri S.Sex Differences in nonalcoholic fatty liver disease: state of the art and identification of research gaps.Hepatology2019;70:1457-69 PMCID:PMC6766425

[45] Lonardo A,Arrese M.Perspectives on precision medicine approaches to NAFLD diagnosis and management.Adv Ther2021;38:2130-58 PMCID:PMC8107169

[46] Lonardo A.Precision medicine in nonalcoholic fatty liver disease.J Gastroenterol Hepatol2022;37:1175-8

[47] Iruzubieta P,Arias-Loste MT.Research priorities for precision medicine in NAFLD.Clin Liver Dis2023;27:535-51

[48] Kantartzis K.Clustering NAFLD: phenotypes of nonalcoholic fatty liver disease and their differing trajectories.Hepatol Commun2023;7:e0112 PMCID:PMC10043573

[49] Lonardo A.The heterogeneity of metabolic syndrome presentation and challenges this causes in its pharmacological management: a narrative review focusing on principal risk modifiers.Expert Rev Clin Pharmacol2023;16:891-911

[50] Francque SM.Towards precision medicine in non-alcoholic fatty liver disease.Rev Endocr Metab Disord2023;24:885-99